PML-RARA t(15;17) bcr1&bcr2, bcr3 Detection Kit
£1,363.00
geneMAP™ PML-RARA T(15;17) Bcr1&Bcr2, Bcr3 Detection Kit for Leukemia are intended for the quantitative detection of PML-RARA bcr1&bcr2 and bcr3, fusion transcripts in bone marrow or peripheral blood samples. The results obtained are intended to be used as an aid to monitor efficacy of treatment in patients undergoing therapy, and for minimal residual disease (MRD) follow-up to monitor disease relapse.
- Superior Analytical Sensitivity: Achieves a log4 reduction, enabling the detection of low levels of the PML-RARA fusion transcript across all breakpoint cluster regions (bcr1, bcr2, bcr3).
- One-Step RT-qPCR Technology: Simplifies the testing process, making it both fast and user-friendly.
- Multiplex PCR: Facilitates accurate relative quantitation by comparing fusion transcripts against ABL1 gene expression, enhancing diagnostic precision.
- Instrument Compatibility: Designed for use with FAM and VIC/HEX dual-color real-time PCR instruments, ensuring broad applicability.
- CE-IVD Certification: Meets European standards for in vitro diagnostic medical devices, ensuring the kit’s reliability and quality.
Leukemia Diagnosis and Monitoring: Specifically targets the PML-RARA fusion gene for patients suspected of or diagnosed with acute promyelocytic leukemia (APL), a subtype of acute myeloid leukemia (AML), playing a key role in diagnosis, prognosis, and treatment monitoring strategies.
- Technology: Utilizes one-step RT-qPCR with multiplex PCR for the detection and relative quantitation of the PML-RARA fusion transcript across bcr1, bcr2, and bcr3.
- Sensitivity: Features superior analytical sensitivity (log4 reduction) for detecting low levels of the target gene.
- Compatibility: Compatible with FAM and VIC/HEX dual-color real-time PCR instruments.
- Certification: Carries the CE-IVD mark, indicating compliance with EU regulations for in vitro diagnostic use.
- Superior Analytical Sensitivity: Achieves a log4 reduction, enabling the detection of low levels of the PML-RARA fusion transcript across all breakpoint cluster regions (bcr1, bcr2, bcr3).
- One-Step RT-qPCR Technology: Simplifies the testing process, making it both fast and user-friendly.
- Multiplex PCR: Facilitates accurate relative quantitation by comparing fusion transcripts against ABL1 gene expression, enhancing diagnostic precision.
- Instrument Compatibility: Designed for use with FAM and VIC/HEX dual-color real-time PCR instruments, ensuring broad applicability.
- CE-IVD Certification: Meets European standards for in vitro diagnostic medical devices, ensuring the kit’s reliability and quality.
Leukemia Diagnosis and Monitoring: Specifically targets the PML-RARA fusion gene for patients suspected of or diagnosed with acute promyelocytic leukemia (APL), a subtype of acute myeloid leukemia (AML), playing a key role in diagnosis, prognosis, and treatment monitoring strategies.
- Technology: Utilizes one-step RT-qPCR with multiplex PCR for the detection and relative quantitation of the PML-RARA fusion transcript across bcr1, bcr2, and bcr3.
- Sensitivity: Features superior analytical sensitivity (log4 reduction) for detecting low levels of the target gene.
- Compatibility: Compatible with FAM and VIC/HEX dual-color real-time PCR instruments.
- Certification: Carries the CE-IVD mark, indicating compliance with EU regulations for in vitro diagnostic use.
Download essential technical information for this product.
Why Choose Clent
We strive to enable our customers to focus on the results of their work, rather than the tools they use. Need to speak with a member of our team? Get in touch today.
